Pembrolizumab-induced bullous pemphigoid.
作者信息
Sun Christina W, Grossman Shoshana K, Aphale Abhishek, Hsu Sylvia
机构信息
Department of Dermatology, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania.
Fox Chase Cancer Center, Temple University Health System, Philadelphia, Pennsylvania.
出版信息
JAAD Case Rep. 2019 Apr 5;5(4):362-364. doi: 10.1016/j.jdcr.2019.02.008. eCollection 2019 Apr.
Abstract
摘要
相似文献
1
Pembrolizumab-induced bullous pemphigoid.
JAAD Case Rep. 2019 Apr 5;5(4):362-364. doi: 10.1016/j.jdcr.2019.02.008. eCollection 2019 Apr.
2
Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature.
Front Med (Lausanne). 2018 Sep 27;5:268. doi: 10.3389/fmed.2018.00268. eCollection 2018.
3
Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.
Expert Opin Drug Saf. 2019 Jul;18(7):623-633. doi: 10.1080/14740338.2019.1619693. Epub 2019 May 22.
4
Development of bullous pemphigoid during nivolumab therapy.
JAAD Case Rep. 2016 Dec 3;2(6):442-444. doi: 10.1016/j.jdcr.2016.05.009. eCollection 2016 Nov.
5
Bullous Pemphigoid as an Adverse Reaction to Pembrolizumab: Two Case Reports.
Case Rep Dermatol. 2018 Jun 5;10(2):154-157. doi: 10.1159/000489661. eCollection 2018 May-Aug.
6
Bullous pemphigoid secondary to pembrolizumab mimicking toxic epidermal necrolysis.
JAAD Case Rep. 2020 Apr 29;6(5):400-402. doi: 10.1016/j.jdcr.2020.03.003. eCollection 2020 May.
7
Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression.
Clin Exp Dermatol. 2017 Apr;42(3):309-312. doi: 10.1111/ced.13042. Epub 2017 Feb 16.
8
Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.
Australas J Dermatol. 2017 Aug;58(3):e109-e112. doi: 10.1111/ajd.12488. Epub 2016 May 11.
9
Nonbullous pemphigoid secondary to PD-1 inhibition.
JAAD Case Rep. 2019 Oct 3;5(10):898-903. doi: 10.1016/j.jdcr.2019.07.015. eCollection 2019 Oct.
10
Pembrolizumab-induced rash in a patient with angiosarcoma.
JAAD Case Rep. 2022 Aug 27;29:21-24. doi: 10.1016/j.jdcr.2022.08.030. eCollection 2022 Nov.
引用本文的文献
1
Steroid resistant bullous pemphigoid induced by pembrolizumab in a patient with metastatic lung adenocarcinoma: case report and review of the literature.
Discov Oncol. 2025 Jul 1;16(1):1195. doi: 10.1007/s12672-025-02377-7.
2
Atypical Presentation of Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) in a Patient on Pembrolizumab: A Case Report.
Cureus. 2024 May 7;16(5):e59804. doi: 10.7759/cureus.59804. eCollection 2024 May.
3
Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid.
Front Oncol. 2023 Mar 3;13:1095694. doi: 10.3389/fonc.2023.1095694. eCollection 2023.
4
Bullous Pemphigoid in Patients Receiving Immune-Checkpoint Inhibitors and Psoriatic Patients-Focus on Clinical and Histopathological Variation.
Dermatopathology (Basel). 2022 Mar 18;9(1):60-81. doi: 10.3390/dermatopathology9010010.
5
Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers.
Front Immunol. 2021 Feb 23;11:588582. doi: 10.3389/fimmu.2020.588582. eCollection 2020.
6
Bullous pemphigoid secondary to pembrolizumab mimicking toxic epidermal necrolysis.
JAAD Case Rep. 2020 Apr 29;6(5):400-402. doi: 10.1016/j.jdcr.2020.03.003. eCollection 2020 May.
本文引用的文献
1
Bullous Pemphigoid as an Adverse Reaction to Pembrolizumab: Two Case Reports.
Case Rep Dermatol. 2018 Jun 5;10(2):154-157. doi: 10.1159/000489661. eCollection 2018 May-Aug.
2
A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors.
Int J Dermatol. 2018 Jun;57(6):664-669. doi: 10.1111/ijd.13984. Epub 2018 Apr 6.
3
Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression.
Clin Exp Dermatol. 2017 Apr;42(3):309-312. doi: 10.1111/ced.13042. Epub 2017 Feb 16.
4
Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.
J Am Acad Dermatol. 2016 Mar;74(3):455-61.e1. doi: 10.1016/j.jaad.2015.10.029. Epub 2016 Jan 12.
5
Immune checkpoint inhibitors: therapeutic advances in melanoma.
Ann Transl Med. 2015 Oct;3(18):267. doi: 10.3978/j.issn.2305-5839.2015.10.27.
6
Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1.
Front Immunol. 2014 May 16;5:206. doi: 10.3389/fimmu.2014.00206. eCollection 2014.
7
Update on the pathogenesis of bullous pemphigoid: an autoantibody-mediated blistering disease targeting collagen XVII.
J Dermatol Sci. 2014 Mar;73(3):179-86. doi: 10.1016/j.jdermsci.2013.12.001. Epub 2013 Dec 27.
8
Drug-induced pemphigoid: a review of the literature.
J Eur Acad Dermatol Venereol. 2014 Sep;28(9):1133-40. doi: 10.1111/jdv.12366. Epub 2014 Jan 10.
9
Antigen identification in drug-induced bullous pemphigoid.
J Am Acad Dermatol. 1993 Nov;29(5 Pt 2):879-82. doi: 10.1016/0190-9622(93)70262-r.
Zotero 插件